[
  {
    "ts": null,
    "headline": "Top Research Reports for Costco, Chubb & Cigna",
    "summary": "Zacks highlights strong prospects for COST, CB, and CI, with Costco's steady growth, Chubb's strategic expansion, and Cigna's solid Q1 performance amid margin pressures.",
    "url": "https://finnhub.io/api/news?id=a36cbd39ee33de24a139969535642cbf150298a99be70e8fa83d740ebc41fae0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748034000,
      "headline": "Top Research Reports for Costco, Chubb & Cigna",
      "id": 134685695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CI",
      "source": "Yahoo",
      "summary": "Zacks highlights strong prospects for COST, CB, and CI, with Costco's steady growth, Chubb's strategic expansion, and Cigna's solid Q1 performance amid margin pressures.",
      "url": "https://finnhub.io/api/news?id=a36cbd39ee33de24a139969535642cbf150298a99be70e8fa83d740ebc41fae0"
    }
  },
  {
    "ts": null,
    "headline": "CI's Unit Unveils Offering to Expand Access to GLP-1 Medications",
    "summary": "Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs for health plan sponsors.",
    "url": "https://finnhub.io/api/news?id=f176762f9ebc32d916e9ea73761b70c9695bb4f33e7bd60da79d074053e5bcff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748027460,
      "headline": "CI's Unit Unveils Offering to Expand Access to GLP-1 Medications",
      "id": 134685899,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CI",
      "source": "Yahoo",
      "summary": "Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs for health plan sponsors.",
      "url": "https://finnhub.io/api/news?id=f176762f9ebc32d916e9ea73761b70c9695bb4f33e7bd60da79d074053e5bcff"
    }
  },
  {
    "ts": null,
    "headline": "Cigna Group stock outperforms competitors on strong trading day",
    "summary": "Cigna Group stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=1b009f738ca181bc244d5005fe23db1dad583b02b5fe433897e689d70702e310",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748018460,
      "headline": "Cigna Group stock outperforms competitors on strong trading day",
      "id": 134723192,
      "image": "",
      "related": "CI",
      "source": "MarketWatch",
      "summary": "Cigna Group stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=1b009f738ca181bc244d5005fe23db1dad583b02b5fe433897e689d70702e310"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers: Not The Dip I Want To Buy (Rating Downgrade)",
    "summary": "Hims & Hers: Not The Dip I Want To Buy (Rating Downgrade)",
    "url": "https://finnhub.io/api/news?id=1db9e06d9c06f486f2e6f420cd95c5103b1889e4834a3b44c3f9d678e683fea4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748002234,
      "headline": "Hims & Hers: Not The Dip I Want To Buy (Rating Downgrade)",
      "id": 134664052,
      "image": "",
      "related": "CI",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1db9e06d9c06f486f2e6f420cd95c5103b1889e4834a3b44c3f9d678e683fea4"
    }
  },
  {
    "ts": null,
    "headline": "Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs",
    "summary": "The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. Beginning in the second half of 2025, the program targets businesses that do not already cover these drugs because of their high […]",
    "url": "https://finnhub.io/api/news?id=ddf5d3cf5461936ad7f95e21f7c0a367d5cc4dc6012b2889a7da0c1f777d77d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747966260,
      "headline": "Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs",
      "id": 134658387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CI",
      "source": "Yahoo",
      "summary": "The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. Beginning in the second half of 2025, the program targets businesses that do not already cover these drugs because of their high […]",
      "url": "https://finnhub.io/api/news?id=ddf5d3cf5461936ad7f95e21f7c0a367d5cc4dc6012b2889a7da0c1f777d77d5"
    }
  }
]